Treatment of parasitic diarrhea in HIV-infected patients

References

• Wilcox CM. Etiology and evaluation of diarrhoea in AIDS: a global perspective at the millennium. World J. Gastroenterol.6(2), 177–186 (2000).
   PubMed Web of Science ®Google Scholar
• Tinmouth J, Kandel G, Tomlinson G, Walmsley S, Steinhart HA, Glazier R. Systematic review of strategies to measure HIV-related diarrhea. HIV Clin. Trials8(3), 155–163 (2007).
   PubMed Web of Science ®Google Scholar
• Lean S, Pollok RC. Management of protozoa-related diarrhea in HIV infection. Expert Rev. Anti Infect. Ther.3, 455–469 (2003).
   Google Scholar
• Wainberg MA, Clotet B. Review: immunologic response to protease inhibitor-based highly active antiretroviral therapy: a review. AIDS Patient Care STDS21(9), 609–620 (2007).
   PubMedGoogle Scholar
• Hunter PR, Hughes S, Woodhouse S et al. Sporadic cryptosporidiosis case–control study with genotyping. Emerg. Infect. Dis.10, 1241–1249 (2004).
   PubMed Web of Science ®Google Scholar
• Semenza JC, Nichols G. Cryptosporidiosis surveillance and water-borne outbreaks in Europe. Euro. Surveill.12, E13–E14 (2007).
   PubMedGoogle Scholar
• Caccio, S, Pozzio E. Advances in the epidemiology, diagnosis and treatment of cryptosporidiosis. Expert. Rev. Anti. Infect. Ther.4, 429–443 (2006).
   PubMedGoogle Scholar
• Dillingham RA, Lima AA, Guerrant RL. Cryptosporidiosis: epidemiology and impact. Microbes Infect.4(10), 1059–1066 (2002).
   PubMed Web of Science ®Google Scholar
• Leoni F, Amar C, Nichols G, Pedraza-Diaz S, McLauchlin J. Genetic analysis of Cryptosporidium from 2414 humans with diarrhoea in England between 1985 and 2000. J. Med. Microbiol.55, 703–707 (2006)
   PubMedGoogle Scholar
• Xiao L, Feng Y. Zoonotic cryptosporidiosis. FEMS Immunol. Med. Microbiol.52, 309–323 (2008).
   PubMedGoogle Scholar
• Chen XM, Keithly JS, Paya CV, LaRusso NF. Cryptosporidiosis. N. Engl. J. Med.346, 1723 (2002).
   PubMed Web of Science ®Google Scholar
• Yoder JS, Beach MJ. Cryptosporidiosis surveillance – United States, 2003–2005. MMWR Surveill. Summ.56, 1–10 (2007).
   PubMedGoogle Scholar
• Xiao L, Ryan UM. Cryptosporidiosis: an update in molecular epidemiology. Curr. Opin. Infect. Dis.17(5), 483–490 (2004).
   PubMed Web of Science ®Google Scholar
• Chalmers RM, Ferguson C, Caccio S et al. Direct comparison of selected methods for genetic categorisation of Cryptosporidium parvum and Cryptosporidium hominis species. Int. J. Parasitol.35, 397–410 (2005).
   PubMed Web of Science ®Google Scholar
• Stroup, SE, Roy S, McHele J et al. Real-time PCR detection and speciation of Cryptosporidium infection using Scorpion probes. J. Med. Microbiol.55, 1217–1222 (2006).
   PubMedGoogle Scholar
• Bandyopadhyay K, Kellar KL, Moura I et al. Rapid microsphere assay for identification of Cryptosporidium hominis and Cryptosporidium parvum in stool and environmental samples. J. Clin. Microbiol.45, 2835–2840 (2007).
   PubMedGoogle Scholar
• Coupe S, Sarfati C, Hamane S, Derouin F. Detection of Cryptosporidium and identification to the species level by nested PCR and restriction fragment length polymorphism. J. Clin. Microbiol.43, 1017–1023 (2005).
   PubMed Web of Science ®Google Scholar
• Caccio SM. Molecular epidemiology of human cryptosporidiosis. Parasitologia47, 185–192 (2005).
   PubMedGoogle Scholar
• Lake IR, Harrison FC, Chalmers RM et al. Case–control study of environmental and social factors influencing cryptosporidiosis. Eur. J. Epidemiol.22, 805–811 (2007).
   PubMedGoogle Scholar
• Lake IR, Nichols G, Bentham GH, Hunter PR, Kovats SR. Cryptosporidiosis decline after regulation, England and Wales, 1989–2005. Emerg. Infect. Dis.13, 623–625 (2007).
   PubMed Web of Science ®Google Scholar
• Hunter PR, Hughes S, Woodhouse S et al. Health sequelae of human cryptosporidiosis in immunocompetent patients. Clin. Infect. Dis.39, 504–510 (2004).
   PubMed Web of Science ®Google Scholar
• Cama, VA, Ross JM, Crawford S et al. Differences in clinical manifestations among Cryptosporidium species and subtypes in HIV-infected persons. J. Infect. Dis.196, 684–691 (2007).
   PubMed Web of Science ®Google Scholar
• Conteas CN, Berlin OGW, Speck CE, Pandhumas SS, Larivière MJ, Fu C. Modification of the clinical course of intestinal microsporidiosis in acquired immunodeficiency syndrome patients by immune status and anti-human immunodeficiency virus therapy. Am. J. Trop. Med. Hyg.58, 555–558 (1998).
   PubMedGoogle Scholar
• Le Moing V, Bissuel F, Costagliola D et al. Decreased prevalence of intestinal cryptosporidiosis in HIV-infected patients concomitant to the widespread use of protease inhibitors. AIDS12, 1395–1397 (1998).
   PubMedGoogle Scholar
• Pozio E, Morales MA. The impact of HIV-protease inhibitors on opportunistic parasites. Trends Parasitol.21(2), 58–63 (2005).
   PubMed Web of Science ®Google Scholar
• Anderson VR, Curran MP. Nitazoxanide: a review of its use in the treatment of gastrointestinal infections Drugs67(13), 1947–1967 (2007).
   PubMed Web of Science ®Google Scholar
• Cai X, Woods KM, Upton S, Zhu G. Application of quantitative real-time reverse transcription-PCR in assessing drug efficacy against the intracellular pathogen Cryptosporidium parvum in vitro. Antimicrob. Agents Chemother.49(11), 4437–4442 (2005).
   PubMed Web of Science ®Google Scholar
• Baishanbo A, Gargala G, Duclos C et al. Efficacy of nitazoxanide and paromomycin in biliary tract cryptosporidiosis in an immunosuppressed gerbil model. J. Antimicrob .Chemother.57(2), 353–355 (2006).
   PubMed Web of Science ®Google Scholar
• Abubakar I, Aliyu SH, Arumugam C, Usman NK, Hunter PR. Treatment of cryptosporidiosis in immunocompromised individuals: systematic review and meta-analysis. Br. J. Clin. Pharmacol.63, 387–393 (2007).
   PubMed Web of Science ®Google Scholar
• Rossignol JF, Hidalgo H, Feregrino M et al. A double-blind placebo controlled study of nitazoxanide in the treatment of cryptosporidial diarrhoea in AIDS patients in Mexico. Trans. R. Soc. Trop. Med. Hyg.92(6), 663–666 (1998).
   PubMed Web of Science ®Google Scholar
• Rossignol JF, Ayoud A, Ayers MS. Treatment of diarrhea caused by Cryptosporidium parvum: a prospective, randomized, double-blind, placebo-controlled study of nitazoxanide. J. Infect. Dis.184(1), 103–106 (2001).
   PubMed Web of Science ®Google Scholar
• Amadi B, Mwiya M, Musuku J et al. Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomized controlled trial. Lancet360(9343), 1375–1380 (2002).
   PubMed Web of Science ®Google Scholar
• Rossignol JF. Nitazoxanide in the treatment of acquired immune deficiency syndrome-related cryptosporidiosis: results of the United States compassionate use program in 365 patients. Aliment Pharmacol. Ther.24(5), 887–894 (2006).
   PubMed Web of Science ®Google Scholar
• Wittenberg DF, Miller NM, van den Ende J. Spiramycin is not effective in treating cryptosporidium diarrhea in infants: results of a double-blind randomized trial. J. Infect. Dis.159(1), 131–132 (1989).
   PubMed Web of Science ®Google Scholar
• Woolf GM, Townsend M, Guyatt G. Treatment of cryptosporidiosis with spiramycin in AIDS. An ‘N of 1’ trial. J. Clin. Gastroenterol.9(6), 632–634 (1987).
   PubMedGoogle Scholar
• Uip DE, Lima ALL, Amato VS, Boulos M, Neto VA, Bem David D. Roxythromycin treatment for diarrhoea caused by Cryptosporidium spp. in patients with AIDS. J. Antimicrob. Chemother.41, S93–S97 (1998).
   PubMedGoogle Scholar
• Sprinz E, Mallman R, Barcellos S, Silbert S, Scheatatsky G, Bem David D. AIDS-related cryptosporidial diarrhoea: an open study with roxythromycin. J. Antimicrob. Chemother.41(Suppl.), S85–S91 (1998).
   PubMedGoogle Scholar
• Dionisio D, Orsi A, Sterrantino G et al. Chronic cryptosporidiosis in patients with AIDS: stable remission and possible eradication after long-term, low dose azithromycin. J. Clin. Pathol.51, 138–142 (1998).
   PubMed Web of Science ®Google Scholar
• Kadappu KK, Nagaraja MV, Rao PV, Shasrty BA. Azithromycin as treatment for cryptosporidiosis in human immunodeficiency virus disease. J. Postgrad. Med.48(3), 179–181 (2002).
   PubMedGoogle Scholar
• Holmberg SD, Moorman AC, Von Bargen JC, Palella FJ, Loveless MO, Ward DJ. Possible effectiveness of clarithromycin and rifabutin for cryptosporidiosis chemoprophylaxis in HIV disease. JAMA279, 384–386 (1998).
   PubMed Web of Science ®Google Scholar
• Fichtenbaum CJ, Zackin R, Feinberg J, Benson C, Griffiths JK; Aids Clinical Trials Group New York Concept Sheet Team 064. Rifabutin but not clarithromycin prevents cryptosporidiosis in persons with advanced HIV infection. AIDS14, 2889–2893 (2000).
   PubMed Web of Science ®Google Scholar
• Gill EE, Fast NM. Assessing the microsporidia–fungi relationship: combined phylogenetic analysis of eight genes. Gene375, 103–109 (2006).
   PubMedGoogle Scholar
• Abreu-Acosta N, Lorenzo-Morales J, Leal-Guio Y et al.Enterocytozoon bieneusi (microsporidia) in clinical samples from immunocompetent individuals in Tenerife, Canary Islands, Spain. Trans. R. Soc. Trop. Med. Hyg.99(11), 848–855 (2005).
   PubMed Web of Science ®Google Scholar
• Didier ES, Maddry JA, Brindley PJ et al. Therapeutic strategies for human microsporidia infections. Expert Rev. Anti Infect. Ther.3, 419–434 (2005).
   PubMedGoogle Scholar
• Chacin-Bonilla L, Panunzio AP, Monsalve-Castillo FM et al. Microsporidiosis in Venezuela: prevalence of intestinal microsporidiosis and its contribution to diarrhea in a group of human immunodeficiency virus-infected patients from Zulia state. Am. J. Trop. Med. Hyg.74(3), 482–486 (2006).
   PubMedGoogle Scholar
• Endeshaw T, Kebede A, Verweij JJ et al. Intestinal microsporidiosis in diarrheal patients infected with human immunodeficiency virus-1 in Addis Ababa, Ethiopia. Jpn J. Infect. Dis.59(5), 306–310 (2006).
   PubMedGoogle Scholar
• Espern A, Morio F, Miegeville M et al. Molecular study of microsporidiosis due to Enterocytozoon bieneusi and Encephalitozoon intestinalis among human immunodeficiency virus-infected patients from two geographical areas: Niamey, Niger, and Hanoi, Vietnam. J. Clin. Microbiol.45(9), 2999–3002 (2007).
   PubMed Web of Science ®Google Scholar
• Samie A, Obi CL, Tzipori S et al. Microsporidiosis in South Africa: PCR detection in stool samples of HIV-positive and HIV-negative individuals and school children in Vhembe district, Limpopo province. Trans. R. Soc. Trop. Med. Hyg.101(6), 547–554 (2007).
   PubMedGoogle Scholar
• Tumwine JK, Kekitiinwa A, Bakeera-Kitaka S et al. Cryptosporidiosis and microsporidiosis in ugandan children with persistent diarrhea with and without concurrent infection with the human immunodeficiency virus. Am. J. Trop. Med. Hyg.73(5), 921–925 (2005).
   PubMed Web of Science ®Google Scholar
• Kotler DP, Orenstein JM. Prevalence of intestinal microsporidiosis in HIV-infected individuals referred for gastroenterological evaluation. Am. J. Gastroenterol.89(11), 1998–2002 (1994).
   PubMedGoogle Scholar
• Molina JM, Sarfati C, Beauvais B et al. Intestinal microsporidiosis in human immunodeficiency virus-infected patients with chronic unexplained diarrhea: prevalence and clinical and biologic features. J. Infect. Dis.167(1), 217–221 (1993).
   PubMedGoogle Scholar
• Leelayoova S, Subrungruang I, Rangsin R et al. Transmission of Enterocytozoon bieneusi genotype a in a Thai orphanage. Am. J. Trop. Med. Hyg.73, 104–107 (2005).
   PubMed Web of Science ®Google Scholar
• Bern C, Kawai V, Vargas D et al. The epidemiology of intestinal microsporidiosis in patients with HIV/AIDS in Lima, Peru. J. Infect. Dis.191(10), 1658–1664. (2005).
   PubMedGoogle Scholar
• Breton J, Bart-Delabesse E, Biligui S et al. New highly divergent rRNA sequence among biodiverse genotypes of Enterocytozoon bieneusi strains isolated from humans in Gabon and Cameroon. J. Clin. Microbiol.45(8), 2580–2589 (2007).
   PubMed Web of Science ®Google Scholar
• Thellier M, Breton J. Enterocytozoon bieneusi in human and animals, focus on laboratory identification and molecular epidemiology. Parasite15 (2008) (In Press).
   PubMedGoogle Scholar
• Botterel F, Minozzi C, Vittecoq D et al. Pulmonary localization of Enterocytozoon bieneusi in an AIDS patient: case report and review. J. Clin. Microbiol.40(12), 4800–4801 (2002).
   PubMedGoogle Scholar
• Pol S, Romana CA, Richard S et al. Microsporidia infection in patients with the human immunodeficiency virus and unexplained cholangitis. N. Engl. J. Med.328(2), 95–99 (1993).
   PubMedGoogle Scholar
• Kotler DP, Orenstein JM. Clinical syndromes associated with microsporidiosis. Adv. Parasit.40, 322–349 (1998).
   Web of Science ®Google Scholar
• Garcia LS. Laboratory identification of the microsporidia. J. Clin. Microbiol.40, 1892–1901 (2002).
   PubMed Web of Science ®Google Scholar
• Sheoran AS, Feng X, Singh I et al. Monoclonal antibodies against Enterocytozoon bieneusi of human origin. Clin. Diagn. Lab. Immunol.12, 1109–1113 (2005).
   PubMedGoogle Scholar
• Mo L, Drancourt M. Monoclonal antibodies for specific detection of Encephalitozoon cuniculi. Clin. Diagn. Lab. Immunol.11, 1060–1063 (2004).
   PubMedGoogle Scholar
• Menotti J, Cassinat B, Porcher R et al. Development of a real-time polymerase-chain-reaction assay for quantitative detection of Enterocytozoon bieneusi DNA in stools specimens from immunocompromised patients with intestinal microsporidiosis. J. Infect. Dis.187(9), 1469–1474 (2003).
   PubMedGoogle Scholar
• Molina JM, Tourneur M, Sarfati C et al. Fumagillin treatment of intestinal microsporidiosis. N. Engl. J. Med.346(25), 1963–1969 (2002).
   PubMed Web of Science ®Google Scholar
• Molina JM, Chastang C, Goguel J et al. Albendazole for treatment and prophylaxis of microsporidiosis due to Encephalitozoon intestinalis in patients with AIDS: a randomized double-blind controlled trial. J. Infect. Dis.177(5), 1373–1377 (1998).
   PubMed Web of Science ®Google Scholar
• Menotti J, Santillana-Hayat M, Cassinat B et al. Inhibitory activity of human immunodeficiency virus aspartyl protease inhibitors against Encephalitozoon intestinalis evaluated by cell culture-quantitative PCR assay. Antimicrob Agents Chemother.49(6), 2362–2366 (2005).
   PubMedGoogle Scholar
• Miao YM, Awad-El-Kariem FM, Franzen C et al. Eradication of cryptosporidia and microsporidia following successful antiretroviral therapy. J. Acquir. Immune Defic. Syndr.25(2), 124–129 (2000).
   PubMed Web of Science ®Google Scholar
• Lafaurie M, Sarfati C, Menotti J et al. Remission of disseminated infection caused by Encephalocytozoon intestinalis with highly active antiretroviral therapy. AIDS17(4), 640–641 (2003).
   PubMedGoogle Scholar
• Didier ES, Stovall ME, Green LC et al. Epidemiology of microsporidiosis: sources and modes of transmission. Vet. Parasitol.126, 145–166 (2004).
   PubMed Web of Science ®Google Scholar
• Graczyk TK, Sunderland D, Tamang L et al. Quantitative evaluation of the impact of bather density on levels of human-virulent microsporidian spores in recreational water. Appl. Environ. Microbiol.73(13), 4095–4099 (2007).
   PubMedGoogle Scholar
• Certad G, Arenas-Pinto A, Pocaterra L et al. Isosporiasis in Venezuelan adults infected with human immunodeficiency virus: clinical characterization. Am. J. Trop. Med. Hyg.69(2), 217–222 (2003).
   PubMed Web of Science ®Google Scholar
• Escobedo AA, Núñez FA. Prevalence of intestinal parasites in Cuban acquired immunodeficiency syndrome (AIDS) patients. Acta Trop.72(1), 125–130 (1999).
   PubMed Web of Science ®Google Scholar
• Lagrange-Xélot M, Porcher R, Sarfati C et al. Isosporiasis in patients with HIV infection in the highly active antiretroviral therapy era in France. HIV Med.9(2), 126–130 (2008).
   PubMedGoogle Scholar
• Lebbad M, Norrgren H, Nauclér A et al. Intestinal parasites in HIV-2 associated AIDS cases with chronic diarrhoea in Guinea-Bissau. Acta Trop.80(1), 45–49 (2001).
   PubMedGoogle Scholar
• Sarfati C, Bourgeois A, Menotti J et al. Prevalence of intestinal parasites including microsporidia in human immunodeficiency virus-infected adults in Cameroon: a cross-sectional study. Am. J. Trop. Med. Hyg.74(1), 162–164 (2006).
   PubMedGoogle Scholar
• Silva CV, Ferreira MS, Borges AS et al. Intestinal parasitic infections in HIV/AIDS patients: experience at a teaching hospital in central Brazil. Scand. J. Infect. Dis.37(3), 211–215 (2005).
   PubMedGoogle Scholar
• Wiwanitkit V. Intestinal parasitic infections in Thai HIV-infected patients with different immunity status. BMC Gastroenterol.1, 3 (2001).
   PubMedGoogle Scholar
• Guiguet M, Furco A, Tattevin P et al. Database on HIV Clinical Epidemiology Group. HIV-associated Isospora belli infection: incidence and risk factors in the French Hospital Database on HIV. HIV Med.8(2), 124–130 (2007).
   PubMedGoogle Scholar
• Forthal DN, Guest SS. Isospora belli enteritis in three homosexual men. Am. J. Trop. Med. Hyg.33(6), 1060–1064 (1984).
   PubMed Web of Science ®Google Scholar
• DeHovitz JA, Pape JW, Boncy M, Johnson WD Jr. Clinical manifestations and therapy of Isospora belli infection in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med.315(2), 87–90 (1986).
   PubMedGoogle Scholar
• French AL, Beaudet LM, Benator DA et al. Cholecystectomy in patients with AIDS: clinicopathologic correlations in 107 cases. Clin. Infect. Dis.21, 852–858 (1995).
   PubMedGoogle Scholar
• Gonzalez-Dominguez J, Roldan R, Villanueva JL et al.Isospora belli reactive arthritis in a patient with AIDS. Ann. Rheum. Dis.53, 618–619 (1994).
   PubMedGoogle Scholar
• Restrepo C, Macher AM, Radany EH. Disseminated extraintestinal isosporiasis in a patient with acquired immune deficiency syndrome. Am. J. Clin. Pathol.87, 536–542 (1987).
   PubMedGoogle Scholar
• Lindsay DS, Dubey JP, Toivio-Kinnucan MA et al. Examination of extraintestinal tissue cysts of Isospora belli. J. Parasitol.83, 620–625 (1997).
   PubMedGoogle Scholar
• Frenkel JK, Silva MB, Saldanha J et al.Isospora belli infection: observation of unicellular cysts in mesenteric lymphoid tissues of a Brazilian patient with AIDS and animal inoculation. J. Eukaryot. Microbiol.50(Suppl.), 682–684 (2003).
   PubMedGoogle Scholar
• Pape JW, Verdier RI, Johnson WD Jr. Treatment and prophylaxis of Isospora belli infection in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med.320, 1044–1047 (1989).
   PubMed Web of Science ®Google Scholar
• Ng E, Markell EK, Fleming RL et al. Demonstration of Isospora belli by acid-fast stain in a patient with acquired immune deficiency syndrome. J. Clin. Microbiol.20, 384–386 (1984).
   PubMedGoogle Scholar
• Berlin OG, Conteas CN, Sowerby TM. Detection of Isospora in the stools of AIDS patients using a new rapid autofluorescence technique. AIDS10, 442–443 (1996).
   PubMedGoogle Scholar
• Franzen C, Müller A, Salzberger B et al. Uvitex 2B stain for the diagnosis of Isospora belli infections in patients with the acquired immunodeficiency syndrome. Arch. Pathol. Lab. Med.120(11), 1023–1025 (1996).
   PubMedGoogle Scholar
• Verdier RI, Fitzgerald DW, Johnson WD Jr et al. Trimethoprim-sulfamethoxazole compared with ciprofloxacin for treatment and prophylaxis of Isospora belli and Cyclospora cayetanensis infection in HIV-infected patients. A randomized, controlled trial. Ann. Intern. Med.132(11), 885–888 (2000).
   PubMed Web of Science ®Google Scholar
• Weiss LM, Perlman DC, Sherman J et al.Isospora belli infection: treatment with pyrimethamine. Ann. Intern. Med.109, 474–475 (1988).
   PubMedGoogle Scholar
• Kayembe K, Desmet P, Henry MC et al. Diclazuril for Isospora belli infection in AIDS. Lancet1, 1397–1398 (1989).
   PubMedGoogle Scholar
• Doumbo O, Rossignol JF, Pichard E et al. Nitazoxanide in the treatment of cryptosporidial diarrhea and other intestinal parasitic infections associated with acquired immunodeficiency syndrome in tropical Africa. Am. J. Trop. Med. Hyg.56, 637–639 (1997).
   PubMed Web of Science ®Google Scholar
• Musey KL, Chidiac C, Beaucaire G et al. Effectiveness of roxithromycin for treating Isospora belli infection. J. Infect. Dis.158, 646 (1988).
   PubMedGoogle Scholar
• Dionisio D, Sterrantino G, Meli M et al. Treatment of isosporiasis with combined albendazole and ornidazole in patients with AIDS. AIDS10, 1301–1302 (1996).
   PubMedGoogle Scholar
• Ashford RW. Occurrence of an undescribed coccidian in man in Papua New Guinea. Ann. Trop. Med. Parasitol.73(5), 497–500 (1979).
   PubMed Web of Science ®Google Scholar
• Blans MC, Ridwan BU, Verweij JJ et al. Cyclosporiasis outbreak, Indonesia. Emerg. Infect. Dis.11(9), 1453–1455 (2005).
   PubMedGoogle Scholar
• Herwaldt BL. Cyclospora cayetanensis: a review, focusing on the outbreaks of cyclosporiasis in the 1990s. Clin. Infect. Dis.31, 1040–1057 (2000).
   PubMed Web of Science ®Google Scholar
• Kumar SS, Ananthan S, Lakshmi P. Intestinal parasitic infection in HIV infected patients with diarrhoea in Chennai. Indian J. Med. Microbiol.20(2), 88–91 (2002).
   PubMedGoogle Scholar
• Manatsathit S, Tansupasawasdikul S, Wanachiwanawin D et al. Causes of chronic diarrhea in patients with AIDS in Thailand: a prospective clinical and microbiological study. J. Gastroenterol.31(4), 533–537 (1996).
   PubMedGoogle Scholar
• Mansfield LS, Gajadhar AA. Cyclospora cayetanensis, a food- and waterborne coccidian parasite. Vet. Parasitol.126(1–2), 73–90 (2004).
   PubMed Web of Science ®Google Scholar
• Pape JW, Verdier RI, Boncy M et al.Cyclospora infection in adults infected with HIV: clinical manifestations, treatment and prophylaxis. Ann. Intern. Med.121, 654–657 (1994).
   PubMed Web of Science ®Google Scholar
• de Gorgolas M, Fortes J, Fernadez Guerrero ML. Cyclospora cayetanensis cholecystitis in a patient with AIDS. Ann. Intern. Med.134, 166 (2001).
   PubMedGoogle Scholar
• Zar FA, El-Bayoumi E, Yungbluth MM. Histologic proof of acalculous cholecystitis due to Cyclospora cayetanensis. Clin. Infect. Dis.33(12), E140–E141 (2001).
   Web of Science ®Google Scholar
• Eberhard ML, Pieniazek NJ, Arrowood MJ. Laboratory diagnosis of Cyclospora infections. Arch. Pathol. Lab. Med.121, 792–797 (1997).
   PubMed Web of Science ®Google Scholar
• Dixon BR, Bussey JM, Parrington LJ et al. Detection of Cyclospora cayetanensis oocysts in human fecal specimens by flow cytometry. J. Clin. Microbiol.43, 2375–2379 (2005).
   PubMedGoogle Scholar
• Kimura K, Kumar Rai S, Takemasa K et al. Comparison of three microscopic techniques for diagnosis of Cyclospora cayetanensis. FEMS Microbiol. Lett.238(1), 263–266 (2004).
   PubMedGoogle Scholar
• Pieniazek NJ, Slemenda SB, da Silva AJ et al. PCR confirmation of infection with Cyclospora cayetanensis. Emerg. Infect. Dis.2, 357–359 (1996).
   PubMed Web of Science ®Google Scholar
• Hussein EM, El-Moamly AA, Dawoud HA et al. Real-time PCR and flow cytometry in detection of Cyclospora oocysts in fecal samples of symptomatic and asymptomatic pediatrics patients. J. Egypt. Soc. Parasitol.37(1), 151–170 (2007).
   PubMedGoogle Scholar
• Verweij JJ, Laeijendecker D, Brienen EAT et al. Detection of Cyclospora cayetanensis in travellers returning from the tropics and subtropics using microscopy and realtime PCR. Int. J. Med. Microbiol.293, 199–202 (2003).
   PubMed Web of Science ®Google Scholar
• Ortega RY, Sterling CR, Gilman RH, Cama VA, Diaz F. Cyclospora species – a new protozoan pathogen of humans. N. Engl. J. Med.328, 1308–1312 (1993).
   PubMed Web of Science ®Google Scholar
• Ali V, Nozaki T. Current therapeutics, their problems, and sulfur-containing-amino-acid metabolism as a novel target against infections by ‘amitochondriate’ protozoan parasites. Clin Microbiol Rev.20(1), 164–187 (2007).
   PubMed Web of Science ®Google Scholar
• Aronson NE, Cheney C, Rholl V et al. Biliary giardiasis in a patient with human immunodeficiency virus. J. Clin. Gastroenterol.33, 167–170 (2001).
   PubMed Web of Science ®Google Scholar
• Nash TE, Ohl CA, Thomas E et al. Treatment of patients with refractory giardiasis. Clin. Infect. Dis.33, 22–28 (2001).
   PubMed Web of Science ®Google Scholar
• Lemee V, Zaharia I, Nevez G et al. Metronidazole and albendazole susceptibility of 11 clinical isolates of Giardia duodenalis from France. J. Antimicrob. Chemother.46, 819–821 (2000).
   PubMed Web of Science ®Google Scholar
• Adagu IS, Nolder D, Warhurst DC et al.In vitro activity of nitazoxanide and related compounds against isolates of Giardia intestinalis, Entamoeba histolytica and Trichomonas vaginalis. J. Antimicrob. Chemother.49, 103–111 (2002).
   PubMed Web of Science ®Google Scholar
• Abboud P, Lemee V, Gargala G et al. Successful treatment of metronidazole- and albendazole-resistant giardiasis with nitazoxanide in a patient with acquired immunodeficiency syndrome. Clin. Infect. Dis.32, 1792–1794 (2001).
   PubMed Web of Science ®Google Scholar
• Dunn LA, Andrews KT, McCarthy JS et al. The activity of protease inhibitors against Giardia duodenalis and metronidazole-resistant Trichomonas vaginalis. Int. J. Antimicrob. Agents.29(1), 98–102 (2007).
   PubMed Web of Science ®Google Scholar
• Lowther SA, Dworkin MS, Hanson DL. Entamoeba histolytica/Entamoeba dispar infections in human immunodeficiency virus-infected patients in the United States. Clin. Infect. Dis.30, 955–959 (2000).
   PubMed Web of Science ®Google Scholar
• Hung CC, Chen PJ, Hsieh SM et al. Invasive amoebiasis: an emerging parasitic disease in patients infected with HIV in an area endemic for amoebic infection. AIDS3, 2421–2428 (1999).
   Google Scholar
• Morán P, Ramos F, Ramiro M et al. Infection by human immunodeficiency virus-1 is not a risk factor for amebiasis. Am. J. Trop. Med. Hyg.73(2), 296–300 (2005).
   PubMed Web of Science ®Google Scholar
• Fotedar R, Stark D, Beebe N et al. Laboratory diagnostic techniques for Entamoeba species. Clin. Microbiol. Rev.20(3), 511–532 (2007).
   PubMed Web of Science ®Google Scholar
• Salles JM, Salles MJ, Moraes LA et al. Invasive amebiasis: an update on diagnosis and management. Expert Rev. Anti Infect. Ther.5(5), 893–901 (2007).
   PubMed Web of Science ®Google Scholar
• Rossignol JF, Kabil SM, El-Gohary Y et al. Nitazoxanide in the treatment of amoebiasis. Trans. R. Soc. Trop. Med. Hyg.101(10), 1025–1031 (2007).
   PubMed Web of Science ®Google Scholar
• Stark DJ, Beebe N, Marriott D, Ellis JT, Harkness J. Dientamoebiasis: clinical importance and recent advances. Trends Parasitol.22(2), 92–96 (2006).
   PubMed Web of Science ®Google Scholar
• Méndez OC, Szmulewicz G, Menghi C, Torres S, González G, Gatta C. Comparison of intestinal parasite infestation indexes among HIV positive and negative populations. Medicina (B. Aires).54(4), 307–310 (1994).
   PubMed Web of Science ®Google Scholar
• Johnson EH, Windsor JJ, Clark CG. Emerging from obscurity: biological, clinical, and diagnostic aspects of Dientamoeba fragilis. Clin. Microbiol. Rev.17(3), 553–570 (2004).
   PubMed Web of Science ®Google Scholar
• Tan KSW. Blastocystis spp. In: Emerging Protozoan Pathogens. NA Khan (Ed.). Taylors and Francis Group, NY, USA 153–189 (2007).
   Google Scholar
• Tan KS. Blastocystis in humans and animals: new insights using modern methodologies. Vet. Parasitol.126(1–2), 121–144 (2004).
   PubMedGoogle Scholar
• Brites C, Barberino MG, Bastos MA et al.Blastocystis hominis as a potential cause of diarrhea in AIDS patients: a report of six cases in Bahia, Brazil. Braz. J. Infect. Dis.1, 91–94 (1997).
   PubMedGoogle Scholar
• Albrecht H, Stellbrink HJ, Koperski K et al.Blastocystis hominis in human immunodeficiency virus-related diarrhea. Scand. J. Gastroenterol.30, 909–914 (1995).
   PubMed Web of Science ®Google Scholar
• Moghaddam DD, Ghadirian E, Azami M. Blastocystis hominis and the evaluation of efficacy of metronidazole and trimethoprim/sulfamethoxazole. Parasitol. Res.96(4), 273–275 (2005).
   PubMed Web of Science ®Google Scholar
• Rossignol JF, Kabil SM, Said M et al. Effect of nitazoxanide in persistent diarrhea and enteritis associated with Blastocystis hominis. Clin. Gastroenterol. Hepatol.3(10), 987–991 (2005).
   PubMedGoogle Scholar
• Stenzel DJ, Boreham PF. Blastocystis hominis revisited. Clin. Microbiol. Rev.9(4), 563–584 (1996).
   PubMed Web of Science ®Google Scholar
• Marcos LA, Terashima A, Dupont HL, Gotuzzo E. Strongyloides hyperinfection syndrome: an emerging global infectious disease. Trans. R. Soc. Trop. Med. Hyg.102(4), 314–318 (2008).
   PubMed Web of Science ®Google Scholar
• Lucas SB. Missing infections in AIDS. Trans. Roy. Soc. Trop. Med. Hyg.84(Suppl.), S34–S38 (1990).
   PubMed Web of Science ®Google Scholar
• Viney ME, Brown M, Omoding NE et al. Why does HIV infection not lead to disseminated strongyloidiasis? J. Infect. Dis.190(12), 2175–2180 (2004).
   PubMed Web of Science ®Google Scholar
• Monkemuller KE, Call SA, Lazenby AJ, Wilcox CM. Declining prevalence of opportunistic gastrointestinal disease in the era of combination antiretroviral therapy. Am. J. Gastroenterol.95(2), 457–462 (2000).
   PubMed Web of Science ®Google Scholar
• Babiker A, Darbyshire J, Pezzotti P et al. Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. Int. J. Epidemiol.31(5), 951–958 (2002).
   PubMed Web of Science ®Google Scholar
• Call SA, Heudebert G, Saag M, Wilcox CM. The changing etiology of chronic diarrhea in HIV-infected patients with CD4 cell counts less than 200 cells/mm3. Am. J. Gastroenterol.95(11), 3142–3146 (2000).
   PubMed Web of Science ®Google Scholar
• Schmidt W, Wahnschaffe U, Schafer M et al. Rapid increase of mucosal CD4 T cells followed by clearance of intestinal cryptosporidiosis in an AIDS patient receiving highly active antiretroviral therapy. Gastroenterology120, 984–987 (2001).
   PubMed Web of Science ®Google Scholar
• Mele R., Gomez Morales MA, Tosini F, Pozio E. Indinavir reduces Cryptosporidium parvum infection in both in vitro and in vivo models. Int. J. Parasitol.33(7), 757–764 (2003).
   PubMed Web of Science ®Google Scholar
• Homers V. Effect of antiretroviral protease inhibitors alone, and in combination with paromomycin, on the excystation, invasion and in vitro development of Cryptosporidium parvum.J. Antimicrob. Chemother.52, 359–364 (2003).
   PubMedGoogle Scholar
• Coombs G.H, Goldberg DE, Klemba M et al. Aspartic proteases of Plasmodium falciparum and other parasitic protozoa as drug targets. Trends Parasitol.17, 532–537 (2001).
   PubMed Web of Science ®Google Scholar
• Walmsley S, Bernstein B, King M et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N. Engl. J. Med.346(26), 2039–2046 (2002).
   PubMed Web of Science ®Google Scholar
• Plasencia LD, Socas MM, Valls RA et al. Terminal ileitis as a manifestation of immune reconstitution syndrome following HAART. AIDS20, 1903–1905 (2006).
   PubMedGoogle Scholar
• Gajdatsy AD, Tay-Kearney ML. Microsporidial keratoconjunctivitis after HAART. Clin. Experiment. Ophthalmol.29(5), 327–329 (2001).
   PubMed Web of Science ®Google Scholar
• Lawn SD. Immune reconstitution disease associated with parasitic infections following initiation of antiretroviral therapy. Curr. Opin. Infect. Dis.20(5), 482–488 (2007).
   PubMed Web of Science ®Google Scholar
• Maynart M, Lievre L, Sow PS et al. Primary prevention with cotrimoxazole for HIV-1-infected adults: results of the pilot study in Dakar, Senegal. J. Acquir. Immune Defic. Syndr.26, 130–136 (2001).
   PubMedGoogle Scholar
• Dworkin MS, Williamson J, Jones JL et al. Prophylaxis with trimethoprim–sulfamethoxazole for human immunodeficiency virus-infected patients: impact on risk for infectious diseases. Clin. Infect. Dis.33, 393–398 (2001).
   PubMed Web of Science ®Google Scholar
• Anglaret X, Chêne G, Attia A et al. Early chemotherapy with trimethoprim–sulfamethoxazole for HIV-1 infected adults in Abidjan, Côte d’Ivoire: a randomized trial. Lancet353, 1463–1468 (1999).
   PubMed Web of Science ®Google Scholar
• Kelly P, Lungu F, Keane E et al. Albendazole chemotherapy for treatment of diarrhea in patients with AIDS in Zambia: a randomised double blind controlled trial. Br. Med. J.312, 1187–1191 (1996).
   PubMedGoogle Scholar
• Zulu I, Kelly P, Njobvu L et al. Nitazoxanide for persistent diarrhoea in Zambian acquired immune deficiency syndrome patients: a randomized controlled trial. Aliment. Pharmacol. Ther.21(6), 757–763 (2005).
   PubMed Web of Science ®Google Scholar